Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Alzheimer's Disease

Acadia’s Alzheimer’s Psychosis Drug Misses Mid‑Stage Goal

The result increases doubt over whether the drug can show a replicable benefit in phase‑3 trials.

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials